CEO Gunilla Osswald presents BioArctic

With patients in focus, BioArctic develops completely new types of drugs (disease modifying) with the aim of stopping or slowing down the progression of Alzheimer’s disease and Parkinson’s disease, based on the company’s antibodies (immunotherapy). BioArctic also develops an innovative potential treatment for complete spinal cord injury.

BioArctic’s business strategy is to build a research portfolio with a number of innovative projects successively reaching a suitable point for entering into partnerships with global pharma companies. Our research and development work is proceeding in line with this strategy.

BioArctic is in a phase of strong development. So far, the year has been characterized by high expectations and enthusiasm in anticipation of the continued development of the company and the projects. The company is collaborating with scientifically leading and financially strong partners in the Alzheimer’s disease and Parkinson’s disease areas, which is a quality mark. BioArctic is developing rapidly with several novel projects in the pipeline and a steady increase in the number of employees and consultants.

Among BioArctic’s five projects for treatment of patients with early stage Alzheimer’s disease, BAN2401, which is run in collaboration with Eisai, is the most advanced. The results from the final analysis of the entire BAN2401 Phase 2b study (18 months data) are expected to be available during the second half of 2018.

Together with research groups at Uppsala University, Sweden, BioArctic is developing a totally new type of tool that enables improved diagnosis of Alzheimer’s disease, monitoring of the progression of the disease and objective measuring of the effect of drug treatment. The company’s ambition is to create a tool that can be used in research and drug development as well as in commercial application.

As a result of the research collaboration with AbbVie in Parkinson’s disease, BioArctic has recruited more employees, gained increased resources and are able to drive the BAN0805 project considerably faster towards clinical studies.

BioArctic’s spinal cord injury project SC0806 is currently in Phase 1/2 clinical trial in patients with complete spinal cord injury.

During 2017 intensive work has been in progress in parallel with the daily operations, as we have been preparing for BioArctic’s introduction on Nasdaq Stockholm. October 12 was the first day of trading with BioArctic’s B-share, and this was of course a historic day for the company. It is with great joy that we welcome new as well as previous shareholders to take part in the continued development of BioArctic in a public environment.

The raised SEK 600 million in connection with the IPO will enable BioArctic to continue the development of new innovative treatments aimed at improving the quality of life of patients suffering from neurodegenerative disorders like Alzheimer’s disease and Parkinson’s disease or patients with complete spinal cord injury. We are looking forward to the important activities that lie ahead.